Accord Seeks To Capitalize On Portfolio And Partnerships
Company Points To Growth That Outperforms Peers
Executive Summary
Accord expects to maintain its historically high growth rates through a “holistic” approach to medicines that covers generics and biosimilars alongside more innovative products, with recent marketing alliances in Europe playing into the firm’s ambitions in the CNS area.
You may also be interested in...
Who’s Hired? Accord’s Burt Moves On
Accord has announced the appointment of a replacement for James Burt, who has stepped down from his role as executive vice-president for the Europe, Middle East and North Africa region. Meanwhile, other organizations including NeuClone, the Medicines Patent Pool, KVK Tech and Strides have also announced executive appointments.
Accord Innovates With Cancer Support App
Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.
Accord Expands CNS Ambitions With Zubsolv Deal
Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.